| 1. |
Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. BMJ 2000;321:805-8.  [ PUBMED]
|
| 2. |
Parkin DM. Global cancer in the year 2009. Lancet Oncol 2010; 2:533-43.
|
| 3. |
Alteri R, Kramer J, Simpson S. Colorectal Cancer Facts and Figures 2014-2016. Atlanta: American Cancer Society, 2014. p. 1-30.
|
| 4. |
National Center Institute. A Snapshot of Colorectal Center; 2005. Available from: http://www.planning Cancer.gov/disease/ColorectaSnapshot.pdf. [Last accessed on 2013 Dec 15].
|
| 5. |
Beahrs OH. Colorectal cancer staging as a prognostic feature. Cancer 1982;50 11 Suppl: 2615-7.
|
| 6. |
Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988;31:33-41.
|
| 7. |
Hannisdal E, Thorsen G. Regression analyses of prognostic factors in colorectal cancer. J Surg Oncol 1988;37:109-12.
|
| 8. |
Gurpinar E, Grizzle WE, Piazza GA. COX-Independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front Oncol 2013;3:181.
|
| 9. |
Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.
|
| 10. |
Ogata Y, Torigoe S, Matono K, Sasatomi T, Ishibashi N, Shida S, et al. Prognostic factors after potentially curative resection in stage II or III colon cancer. Kurume Med J 2005;52:67-71.
|
| 11. |
Liang JL, Wan DS, Pan ZZ, Zhou ZW, Chen G, Li LR, et al. Multivariate regression analysis of recurrence following curative surgery for colorectal cancer. Ai Zheng 2004;23:564-7.
|
| 12. |
Yamamoto Y, Takahashi K, Yasuno M, Sakoma T, Mori T. Clinicopathological characteristics of skipping lymph node metastases in patients with colorectal cancer. Jpn J Clin Oncol 1998;28:378-82.
|
| 13. |
Hojo K, Koyama Y. Postoperative follow-up studies on cancer of the colon and rectum. Am J Surg 1982;143:293-3.  [ PUBMED]
|
| 14. |
Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010;91:104-12.
|
| 15. |
Asero R, Quaratino D. Cutaneous hypersensitivity to multiple NSAIDs: Never take tolerance to selective COX-2 inhibitors (COXIBs) for granted! Eur Ann Allergy Clin Immunol 2013;45:3-6.
|
| 16. |
Jung HJ, Cho YW, Lim HW, Choi H, Ji DJ, Lim CJ. Anti-Inflammatory, antioxidant, anti-angiogenic and skin whitening activities of Phryma leptostachya var. Asiatica hara extract. Biomol Ther (Seoul) 2013;21:72-8.
|
| 17. |
Yamac D, Celenkoglu G, Coskun U, Akyurek N, Akcali Z, Dursun A, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 2005;201:497-502.
|
| 18. |
Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008;97:51-6.
|
| 19. |
Zhan J, Liu JP, Zhu ZH, Yao HR, Chen CY. Relationship between COX-2 expression and clinicopathological features of colorectal cancers. Chin Med J (Engl) 2004;117:1151-4.
|
| 20. |
Yoshinaga M, Taki K, Somada S, Sakiyama Y, Kubo N, Kaku T, et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci 2011;56:1194-200.
|
| 21. |
Miladi-Abdennadher I, Abdelmaksoud-Dammak R, Ayed-Guerfali DB, Ayadi L, Khabir A, Amouri A, et al. Expression of COX-2 and E-cadherin in Tunisian patients with colorectal adenocarcinoma. Acta Histochem 2012;114:577-81.
|